KRAS and cancer: By focusing on these invariant amino acid residues and conserved functional motifs identified in the SINA/SIAH superfamily, we aim to design a phylogenetic-based, targeted and more specific anti-SIAH-based anticancer strategy to both impede and eradicate oncogenic K-RAS-driven metastatic human cancers for clinical translation in the future.